(Q33890298)

29 July 2017

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease (English)

1 reference

autosomal dominant polycystic kidney disease

29 July 2017

0 references

autosomal dominant polycystic kidney

1 reference

Maria V Irazabal

1

1 reference

29 July 2017

Vicente E Torres

2

1 reference

29 July 2017

Marie C Hogan

3

1 reference

29 July 2017

James Glockner

4

1 reference

29 July 2017

Bernard F King

5

1 reference

29 July 2017

Troy G Ofstie

6

1 reference

29 July 2017

Holly B Krasa

7

1 reference

29 July 2017

John Ouyang

8

1 reference

29 July 2017

Frank S Czerwiec

9

1 reference

29 July 2017

language of work or name

English

0 references

publication date

4 May 2011

1 reference

29 July 2017

1 reference

29 July 2017

80

1 reference

29 July 2017

295-301

1 reference

29 July 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2011.119

29 July 2017

0 references

cites work

Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Renal Versus Hindquarter Hemodynamic Responses to Vasopressin in Conscious Rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

The effect of AVP-V receptor stimulation on local GFR in the rat kidney

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Control of the renal medullary circulation by vasopressin V1 and V2 receptors in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

The effect of antidiuretic hormone on the distribution of nephron filtration rates in rats with hereditary diabetes insipidus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Intrarenal distribution of blood flow in diabetes insipidus: role of ADH

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Effect of AVP.V1-receptor antagonist on urinary albumin excretion and renal hemodynamics in NIDDM nephropathy: role of AVP.V1-receptor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Effect of arginine vasopressin on renal medullary blood flow. A videomicroscopic study in the rat

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Mechanisms of action of various hormones and vasoactive substances on glomerular ultrafiltration in the rat

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Level of hydration and renal function in healthy humans.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

The secretion of fluid by renal cysts from patients with autosomal dominant polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Hyperuricemia as a clue for central diabetes insipidus (lack of V1 effect) in the differential diagnosis of polydipsia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Hyperuricemia, a concomitant of congenital vasopressin-resistant diabetes insipidus in the adult

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Long-term effects of vasopressin on the subcellular localization of ENaC in the renal collecting system

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Short-term stimulation of the thiazide-sensitive Na+-Cl- cotransporter by vasopressin involves phosphorylation and membrane translocation.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Potassium transport in the mammalian collecting duct

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Unified criteria for ultrasonographic diagnosis of ADPKD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Total body water reference values and prediction equations for adults

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Renal arterial blood flow measurement by breath-held MRI: Accuracy in phantom scans and reproducibility in healthy subjects.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.119

7 January 2021

Identifiers

DOI

10.1038/KI.2011.119

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference